Valsts: Malaizija
Valoda: angļu
Klimata pārmaiņas: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
CABAZITAXEL 60MG/1.5ML
SANOFI-AVENTIS (MALAYSIA) SDN. BHD.
CABAZITAXEL 60MG/1.5ML
1Units Units; 1Units Units
Sanofi-Aventis Deutschland GmbH
NAME OF THE MEDICINAL PRODUCT JEVTANA 60 mg concentrate and solvent for solution for infusion. _ _ QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate contains 40 mg cabazitaxel. Each vial of 1.5 ml (nominal volume) of concentrate contains 60 mg cabazitaxel. After initial dilution with the entire solvent, each ml of solution contains 10 mg cabazitaxel. Note: Both the JEVTANA 60 mg/1.5 ml concentrate vial (fill volume: 73.2 mg of cabazitaxel/1.83 ml) and the solvent vial (fill volume: 5.67 ml) contain an overfill to compensate for liquid loss during preparation. This overfill ensures that after dilution with the ENTIRE contents of the accompanying solvent, there is solution containing 10 mg/ml cabazitaxel. Excipients with known effect: Each vial of solvent contains 573.3 mg of ethanol 96%. For the full list of excipients, see section _List of Excipients_ . PHARMACEUTICAL FORM Concentrate and solvent for solution for infusion (sterile concentrate). The concentrate is a clear yellow to brownish-yellow oily solution. The solvent is a clear and colourless solution. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS JEVTANA in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen (see section _Pharmacodynamic Properties_ ). POSOLOGY AND METHOD OF ADMINISTRATION The use of JEVTANA should be confined to units specialised in the administration of cytotoxics and it should only be administered under the supervision of a physician experienced in the use of anticancer chemotherapy. Facilities and equipment for the treatment of serious hypersensitivity reactions like hypotension and bronchospasm must be available (see section _Special Warnings and Precautions for Use_ ). Premedication The recommended premedication regimen should be performed at least 30 minutes prior to each administration of JEVTANA with the following intravenous medicinal products to mitigate the risk and sev Izlasiet visu dokumentu